Volastra Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company’s internally ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

A year of recovery After a challenging period, 2024 has seen a more positive backdrop emerge for the biotechnology sector. In ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. (BMS) in a research collaboration and license agreement totaling $3.61 billion. The two companies ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...